stage 3

UNDERSTANDING DATO-DXd CLINICAL TRIAL RESULTS IN NSCLC

This document summarizes key clinical trial findings for Dato-DXd in non-small cell lung cancer (NSCLC), focusing on results from two studies: the Phase II TROPION-Lung05 and the Phase III TROPION-Lung01 trials. Special attention is given to the outcomes in patients with EGFR-mutated disease, including a deeper analysis of Dato-DXd’s potential role in this molecular subgroup.

UNDERSTANDING DATO-DXd CLINICAL TRIAL RESULTS IN NSCLC Read More »

Your Guide to Biomarkers and Associated Therapies in NSCLC

The landscape of non-small cell lung cancer (NSCLC) treatment has dramatically evolved with the identification of specific genetic alterations that drive tumor growth. These molecular biomarkers have enabled the development of targeted therapies that significantly improve patient outcomes compared to traditional chemotherapy. This report provides a comprehensive overview of established and emerging biomarkers in NSCLC

Your Guide to Biomarkers and Associated Therapies in NSCLC Read More »

Overcome Stage IIIC Ovarian Cancer After 2 years of Misdiagnosis

Charlotte is 31 years old. Diagnosed with ovarian cancer at 27, discovered after an intestinal obstruction, she went through numerous challenges before embarking on the most significant professional project of her life: a social and solidarity-based start-up aimed at gently supporting cancer fighters. Here is a meeting with an entrepreneur brimming with life.

Overcome Stage IIIC Ovarian Cancer After 2 years of Misdiagnosis Read More »